Clinical Trials - Impact of COVID-19 and Long COVID
Summary
This report provides an overview of global COVID-19 clinical trials, long COVID clinical trials, and trials disrupted by COVID-19.
Scope
The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data was captured in the database as of April 12, 2023. The data was analyzed and segmented by COVID-19 trials, COVID-19 trials for vaccines and therapeutics, and long COVID trials. An analysis was also completed on non-COVID trials impacted due to the pandemic.
Reasons to Buy
Trends of COVID-19 trials through the years
Comparison of trials by phase, sponsor type and status
Geographic analysis
Focus on top sponsors for vaccine and therapeutic trials
Long COVID analysis
COVID-19 impact on trials
Executive Summary
Introduction
Report Scope
Methodology
COVID-19 Cases & Deaths Continue but at a Lower Rate
COVID-19 Clinical Trials Analysis
COVID-19 Clinical Trials Starts per Month Continue to Decline
Single-Country COVID-19 Trials Dominate
Asia-Pacific Continues to Dominate Single-Country Trials
Europe Still Has the Most Multinational Clinical Trials
North America Has the Most Clinical Trial Sites
Slight Change in Order of US States for COVID-19 Sites
Phase II and Now Completed Trials Dominate the Landscape of COVID-19 Trials
Primary Endpoints Continue to Be Achieved
Low Accrual Rate Was the Primary Cause for Trial Termination
Low Accrual Rate Was the Primary Cause for Trial Termination by Sponsor Type
COVID-19 Clinical Trials for Vaccines & Therapeutics
The Amount of Vaccine COVID-19 Clinical Trials Changes Over Time
Therapeutic COVID-19 Trials Decline More
Phase II Has Most Trials for Vaccine & Therapeutic COVID-19 Clinical Trials
Vaccine & Therapeutic COVID-19 Clinical Trials See the Most Trials in Different Trial Statuses
Sinovac Biotech Still Top Industry Sponsor for Vaccine Trials
Finlay Vaccine Institute Is the Top Non-industry Vaccine Trial Sponsor
Sorrento Therapeutics Is Top Industry Sponsor for COVID-19 Therapeutics Trials
Universities Still Top Non-industry Sponsors
Long COVID Analysis
Attention Has Turned to Long COVID
Majority of Long COVID Trials Are Ongoing
North America Also Has Most Long COVID Sites
US and Florida Top Long COVID Sites by Country and State
A Wide Range of Sponsor Types for Long COVID Trials
Colchicine Is Top Drug Tested for Long COVID
Phase II Trial Completions Expected Most in Upcoming Long COVID Events
Impact of COVID-19 on Clinical Trials
Clinical Trials Disrupted Due to COVID-19
Central Nervous System Leads All Therapy Areas in Disrupted Trials
Where Is the Most Disruption of Clinical Trials?
Emory University Is Top Sponsor with Most Disruption
Resumed Clinical Trials Increasing
Increased Use of Decentralized Clinical Trials
Central Nervous System Utilizes DCTs the Most
The Top Industry Sponsor Using DCTs Is GlaxoSmithKline
University of Oxford and Duke University Top Non-industry Sponsors for DCTs
Telemedicine Is the Most Used DCT Component
More Real-World Evidence Used After the Pandemic
Key Findings
Appendix
List of Tables
Table 1: Total Number of COVID-19 cases and deaths
List of Figures
Figure 1: Total number of COVID-19 cases and deaths
Figure 2: Number of COVID-19 clinical trials by start date, by month
Figure 3: Number of COVID-19 clinical trials, by multinational versus single-country
Figure 4: Single-country COVID-19 clinical trials, by region and phase
Figure 5: Multinational COVID-19 clinical trials, by region and phase
Figure 6: COVID-19 clinical trial sites, by region
Figures 7 & 8: COVID-19 clinical trial sites, by country and state
Figures 9 & 10: Number of COVID-19 clinical trials, by phase and status
Figure 11: Endpoint status for completed COVID-19 clinical trials
Figure 12: Top reasons for terminated trials, by phase
Figure 13: Top reason for terminated trials, by sponsor type
Figure 14: COVID-19 vaccine clinical trials, by trial start date
Figure 15: COVID-19 therapeutic clinical trials, by trial start date